Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 27;7(2):250-252.
doi: 10.3889/oamjms.2019.063. eCollection 2019 Jan 30.

Effectiveness, Safety and Tolerance of Methotrexate in Vietnamese Psoriatic Arthritis Patients

Van Bui Thi  1 , Vinh Ngo Minh  2 , Anh Tran Ngoc  2 , Quyet Tran Dang  3 , Diep Le Ngoc  4 , Em Dang Van  5 , Thuong Nguyen Van  6 , Phuong Pham Thi Minh  6 , Hien Do Thi Thu  6 , Nghi Dinh Huu  6 , My Le Huyen  1 , Khang Tran Hau  6 , Marco Gandolfi  7 , Francesca Satolli  7 , Claudio Feliciani  7 , Michael Tirant  8   9 , Aleksandra Vojvodic  10 , Torello Lotti  8
Affiliations

Effectiveness, Safety and Tolerance of Methotrexate in Vietnamese Psoriatic Arthritis Patients

Van Bui Thi et al. Open Access Maced J Med Sci. .

Abstract

Aim: To access the effectiveness, safety and tolerance of methotrexate (MTX) in psoriatic arthritis (PsA) treatment.

Methods: We recruit 37 patients, admitted at HCMC Hospital of Dermato-Venereology from 1/2016 to 3/2017, with MTX dosage ranging from 10 mg to 15 mg per week.

Results: Skin lesion response after 12 weeks improved PASI 50: 40.5%, PASI 75: 24.3%. Disease activity score decreased after 12 weeks with ∆DAS28 = -1.43 + 0.79, 37.8% PsA achieved complete remission. Nausea and vomiting were 8.1%. These symptoms were mild and transient. We did not stop MTX usage. The rate of elevating SGPT 2-3 times as much as the upper limit of the normal range was 2.7%.

Conclusion: We finally demonstrated that the rate of treatment response in Vietnam is the same as demonstrated by foreign authors in other countries.

Keywords: Disease activity score (DAS); Psoriatic arthritis (PsA).

PubMed Disclaimer

References

    1. Gossec L, Smolen JS, Ramiro S, De Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies:2015 update. Annals of the rheumatic diseases. 2016;75(3):499–510. https://doi.org/10.1136/annrheumdis-2015-208337 PMid:26644232. - PubMed
    1. Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. The Journal of rheumatology. 2016;43(2):356–61. https://doi.org/10.3899/jrheum.150614 PMid:26669913 PMCid:PMC4740927. - PMC - PubMed
    1. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany:a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. British Journal of Dermatology. 2009;160(5):1040–7. https://doi.org/10.1111/j.1365-2133.2008.09023.x PMid:19210498. - PubMed
    1. Moll JM. The clinical spectrum of psoriatic arthritis. Clinical orthopaedics and related research. 1979;143:66–75. https://doi.org/10.1097/00003086-197909000-00010. - PubMed
    1. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, Mulherin DM, Kitas GD, Chakravarty K, Tom BD, O'keeffe AG. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. 2012;51(8):1368–77. https://doi.org/10.1093/rheumatology/kes001 PMid:22344575 PMCid:PMC3397466. - PMC - PubMed

LinkOut - more resources